rethinkPeptides Search
Menu
Study breakdown

New Light-Activated Tool Reveals How Peptide Drugs Interact with Stabilizers in Freeze-Dried Formulations

evidence
The takeaway

Photoreactive excipient analogs can map how peptide drugs like salmon calcitonin interact with stabilizers in freeze-dried pharmaceutical products, replacing trial-and-error formulation.

Different probes, different interaction maps

Sugar-based and amino acid-based photoreactive probes labeled different sites on salmon calcitonin, proving that different types of excipients interact with peptides through distinct mechanisms in freeze-dried solids.

What the researchers found

Two photoreactive excipient analogs — photo-leucine (pLeu, an amino acid analog) and photo-glucosamine (pGlcN, a sugar analog) — showed distinctly different labeling patterns on salmon calcitonin in lyophilized solids. The extent and specific sites of labeling on the peptide differed between the two probes, demonstrating that ionizable and nonionizable excipients interact with the peptide through different mechanisms.

The distribution of photo-reaction products was also influenced by the type of unlabeled excipient present (sucrose vs. histidine) and the pre-lyophilization pH (tested from 6 to 9.9), indicating that formulation conditions meaningfully change how excipients contact the peptide in the solid state.

Why it matters

Peptide therapeutics are one of the fastest-growing drug categories, but formulating them for stability remains a major challenge. Currently, choosing excipients (stabilizers, bulking agents, buffers) is largely trial-and-error because there have been few tools to directly observe how these molecules interact with peptides in the solid state. This photolytic labeling approach could transform peptide drug formulation into a more rational, evidence-based process — potentially reducing development costs and improving drug shelf life.

How the study worked

Researchers incorporated diazirine-derived photoreactive probes — commercially available photo-leucine and custom-synthesized photo-glucosamine — into freeze-dried solids containing salmon calcitonin along with standard excipients (sucrose or histidine). Samples were prepared at pH values ranging from 6 to 9.9 before lyophilization. UV light exposure (365 nm for 30-60 minutes) activated the probes, causing them to form covalent bonds with nearby peptide residues. The resulting labeled products were identified and quantified using liquid chromatography-mass spectrometry.

What this study cannot tell us

This is a proof-of-concept study using a single model peptide (salmon calcitonin). The photoreactive probes may alter the native interactions they're trying to measure by introducing bulky chemical groups. The UV exposure required could potentially cause photodegradation of the peptide itself. The study demonstrates the method's feasibility but does not yet show it can predict formulation stability or guide real-world drug development decisions.

How to read the evidence

This is a laboratory proof-of-concept study demonstrating a new analytical method. The experimental design is sound, using multiple conditions (pH, excipient types, probe types) and validated by mass spectrometry. However, as a methods development paper, it does not address clinical or therapeutic outcomes.

When this study was published

Published in 2020, this study introduced a novel analytical approach for peptide formulation science. The method may have been adopted or refined by other groups since publication.

The bigger picture

As more peptide and protein therapeutics reach the market — from GLP-1 agonists to antibody fragments — the science of formulation becomes increasingly important. Many biologics require lyophilization for storage stability, but degradation during storage remains a common problem. Tools that reveal molecular-level interactions between drugs and excipients in the solid state address a fundamental gap in pharmaceutical science and could accelerate the development of more stable peptide drug products.

Questions still open

  • Can this photolytic labeling approach be applied to larger therapeutic proteins and antibodies in lyophilized formulations?
  • Do the peptide-excipient interaction patterns revealed by this method correlate with long-term storage stability?
  • Could this technique identify novel excipients that provide better peptide stabilization than current options?

Common questions

Why do peptide drugs need to be freeze-dried?
Many peptide drugs are unstable in liquid form — they can degrade, aggregate, or lose their shape over time. Freeze-drying (lyophilization) removes water and locks the drug in a solid state where it's much more stable for storage and shipping. However, the process itself can damage the peptide, which is why choosing the right stabilizer excipients is so important.
How does this light-activated probe technique work?
The researchers created chemical analogs of common drug stabilizers that contain a light-sensitive group called a diazirine. When exposed to UV light, this group becomes highly reactive and instantly bonds to whatever molecule is closest — in this case, the peptide drug. By analyzing where on the peptide these bonds form, scientists can map exactly which parts of the drug are in contact with the stabilizer in the freeze-dried solid.

Read the original research

A Novel Photoreactive Excipient to Probe Peptide-Matrix Interactions in Lyophilized Solids.

Journal of pharmaceutical sciences, 109(1), 709-718

Citation

Chen, Yuan; Topp, Elizabeth M. (2020). A Novel Photoreactive Excipient to Probe Peptide-Matrix Interactions in Lyophilized Solids.. Journal of pharmaceutical sciences, 109(1), 709-718. https://doi.org/10.1016/j.xphs.2019.04.024